AHR three-lens brief
Evidence-based stock research on AHR. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 98% of its 52-week range — near the top of the band.
- Trading at 98% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- RSI at 72 — technically overbought.
- Outperforming SPY by 15.9pp over 30 days.
- P/E of 121 — priced for high growth; little margin of safety.
AHR closed at $59.23 (-0.27%) as of 2026-11-12. Market cap: $13.75B. P/E (trailing) 120.9. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 15.9pp over 30 days.. Concerns: trading at 98% of its 52-week range — near the top of the band.; rSI at 72 — technically overbought.. Last quarter: Revenue $742.15M, net income $31.21M, free cash flow $429.86M.
Why three lenses on AHR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AHR across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/AHR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AHR brief"></iframe>